Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2024-02-27 Capital/Financing Update
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Tarsus Pharmaceuticals, Inc. It registers additional shares under the company's 2020 Equity Incentive Plan. The document includes legal and corporate governance information, indemnification provisions, and references to prior filings. Form S-8 is a specific SEC filing used to register securities to be offered under employee benefit plans. This is not a financial report, earnings release, or management discussion, but a capital market filing related to share registration and equity incentive plans. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is the filing itself, not just an announcement or reference to another report.
2024-02-27 English
10-K
Annual Report FY 2023
2024-02-27 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 27, 2024, reporting the results of operations for the year ended December 31, 2023. It specifically states that the information is furnished under Item 2.02 (Results of Operations and Financial Condition) and includes a press release as Exhibit 99.1. The document explicitly notes that the information is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act, indicating it is a current report rather than a full annual or quarterly report. The length of the document is 3656 characters, which is relatively short and primarily contains the announcement and the press release reference. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is Earnings Release (ER).
2024-02-27 English
AMENDMENT NO. 2
Major Shareholding Notification
2024-02-14 English
AMENDMENT NO. 4
Major Shareholding Notification
2024-02-14 English
TARSUS PHARMACEUTICALS, INC.
Major Shareholding Notification
2024-02-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.